Virologist Dies

The editor-in-chief of the open access journal Retrovirology has passed away unexpectedly.

By | February 8, 2013

Kuan-Teh JeangNIAIDShocking news to many virologists came a few days ago when it was announced that Kuan-Teh Jeang, a researcher at the National Institute of Allergy and Infectious Diseases (NIAID) passed away (January 27) at the age of 54.  Reports have not specified the cause of death.

“Teh’s death is a blow to the NIH and the retrovirus research community; and our thoughts and condolences are with Teh’s family,” Michael Gottesman, deputy director for intramural research at the National Institutes of Health (NIH), wrote in a letter to staff that was published on the Retrovirology blog.

Jeang’s lab studied the factors that influenced the spread of retroviruses such as HIV and human T-lymphotropic virus (HTLV-1), which is known to cause leukemia and lymphoma. He authored more than 300 papers and was cited some 15,000 times, according to ISI Web of Science. He was a strong proponent of open access publishing, and in 2004 started the journal Retrovirology, which became the highest ranked journal in the field, according to one blog. Jeang was awarded BioMed Central’s  Open Access “Editor of the Year” award for his efforts in 2010. 

He is survived by his wife, Diane, and three children, David, John and Diana.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech